Genome-wide identification and characterization of long non-coding RNAs involved in acquired resistance to gefitinib in non-small-cell lung cancer

Acquired resistance is a major obstacle to the therapeutic efficacy of gefitinib in non-small-cell lung cancer (NSCLC). Current knowledge about the role of long non-coding RNAs (lncRNAs) in this phenomenon is insufficient. In this study, we searched RNA sequencing data for lncRNAs associated with acquired resistance to gefitinib in NSCLC, and constructed a functional lncRNA-mRNA co-expression network and protein-protein interaction (PPI) network to analyze their putative target genes and biological functions. The expression levels of 14 outstanding dysregulated lncRNAs and mRNA were verified using real-time PCR. Changes in the expression levels of 39 lncRNAs and 121 mRNAs showed common patterns in our two pairs of gefitinib-sensitive and gefitinib-resistant NSCLC cell lines. The co-expression network included 1235 connections among these common differentially expressed lncRNAs and mRNAs. The significantly enriched signaling pathways based on dysregulated mRNAs were mainly involved in the Hippo signaling pathway; proteoglycans in cancer; and valine, leucine, and isoleucine biosynthesis. The results show that LncRNAs play an important part in acquired gefitinib resistance in NSCLC by regulating mRNA expression and function, and may represent potential new molecular biomarkers and therapeutic targets for gefitinib-resistant NSCLC.

[1]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[2]  E. Birney,et al.  Pfam: the protein families database , 2013, Nucleic Acids Res..

[3]  K. Koike,et al.  Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma , 2018, International journal of molecular sciences.

[4]  Chunlu Yang,et al.  RETRACTED ARTICLE: The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC , 2018, Cell cycle.

[5]  R. McCormack,et al.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study , 2013, British Journal of Cancer.

[6]  Yuan-Fei Liu,et al.  High expression of long intergenic non-coding RNA LINC00662 contributes to malignant growth of acute myeloid leukemia cells by upregulating ROCK1 via sponging microRNA-340-5p. , 2019, European journal of pharmacology.

[7]  Wei Zhao,et al.  Long noncoding RNA NSCLCAT1 increases non–small cell lung cancer cell invasion and migration through the Hippo signaling pathway by interacting with CDH1 , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  H. Kwok,et al.  Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI–Mediated Anticancer Activity in NSCLC , 2019, Translational oncology.

[9]  J. Riess,et al.  Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. , 2014, Clinical lung cancer.

[10]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[11]  F. Liu,et al.  Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p , 2019, DNA and cell biology.

[12]  L. J. Lee,et al.  PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway , 2018, Cellular Physiology and Biochemistry.

[13]  F. Cappuzzo,et al.  Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. , 2011, Lung cancer.

[14]  C. Ki,et al.  Correct use of repeated measures analysis of variance. , 2009, The Korean journal of laboratory medicine.

[15]  Shun Lu,et al.  STAT1-induced upregulation of LINC00467 promotes the proliferation migration of lung adenocarcinoma cells by epigenetically silencing DKK1 to activate Wnt/β-catenin signaling pathway. , 2019, Biochemical and biophysical research communications.

[16]  L. Kleinberg,et al.  NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors , 2017, Genes & cancer.

[17]  Lihua Huang,et al.  Mechanisms of resistance to EGFR tyrosine kinase inhibitors , 2015, Acta pharmaceutica Sinica. B.

[18]  T. Jiang,et al.  Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer , 2016, Oncotarget.

[19]  Minoru Kanehisa,et al.  New approach for understanding genome variations in KEGG , 2018, Nucleic Acids Res..

[20]  Shusen Zheng,et al.  The Hippo pathway as a drug target in gastric cancer. , 2018, Cancer letters.

[21]  Wenya Li,et al.  The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression , 2015, Journal of Hematology & Oncology.

[22]  Y. Li,et al.  HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer , 2018, Cancer science.

[23]  W. Fan,et al.  Identification of chemoresistance-associated miRNAs in breast cancer , 2018, Cancer management and research.

[24]  Yan Wang,et al.  Long non-coding RNA NEAT1-modulated abnormal lipolysis via ATGL drives hepatocellular carcinoma proliferation , 2018, Molecular Cancer.

[25]  Liang Jin,et al.  LncRNA NEAT1 Silenced miR-133b Promotes Migration and Invasion of Breast Cancer Cells , 2019, International journal of molecular sciences.

[26]  A. Rapraeger.  Synstatin: a selective inhibitor of the syndecan‐1‐coupled IGF1R–αvβ3 integrin complex in tumorigenesis and angiogenesis , 2013, The FEBS journal.

[27]  Christian von Mering,et al.  STRING: known and predicted protein–protein associations, integrated and transferred across organisms , 2004, Nucleic Acids Res..

[28]  A. Bhan,et al.  Long Noncoding RNA and Cancer: A New Paradigm. , 2017, Cancer research.

[29]  R. Kream,et al.  Comparing Bioinformatic Gene Expression Profiling Methods: Microarray and RNA-Seq , 2014, Medical science monitor basic research.

[30]  Yuqing Wei,et al.  Long intergenic non-coding RNA 00467 promotes lung adenocarcinoma proliferation, migration and invasion by binding with EZH2 and repressing HTRA3 expression , 2019, Molecular medicine reports.

[31]  Yong Zhang,et al.  CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine , 2007, Nucleic Acids Res..

[32]  Chenghe Lin,et al.  LncRNA TNRC6C‐AS1 regulates UNC5B in thyroid cancer to influence cell proliferation, migration, and invasion as a competing endogenous RNA of miR‐129‐5p , 2018, Journal of cellular biochemistry.

[33]  Hong Liu,et al.  LncRNA SNHG10 facilitates hepatocarcinogenesis and metastasis by modulating its homolog SCARNA13 via a positive feedback loop. , 2019, Cancer research.

[34]  S. Rose-John,et al.  ADAM17: An Emerging Therapeutic Target for Lung Cancer , 2019, Cancers.

[35]  Elizabeth Tipton,et al.  Robust variance estimation with dependent effect sizes: practical considerations including a software tutorial in Stata and spss , 2014, Research synthesis methods.

[36]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[37]  Mayuko Shimoda,et al.  The Emerging Link between the Hippo Pathway and Non-coding RNA. , 2020, Biological & pharmaceutical bulletin.

[38]  Weimin Fan,et al.  A novel mRNA-miRNA-lncRNA competing endogenous RNA triple sub-network associated with prognosis of pancreatic cancer , 2019, Aging.

[39]  Daniel R. Mitteer,et al.  Teaching behavior technicians to create publication-quality, single-case design graphs in graphpad prism 7. , 2018, Journal of applied behavior analysis.

[40]  Yeon-Hee Park,et al.  Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. , 2016, Biochemical and biophysical research communications.

[41]  Qingchun Zhao,et al.  Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo. , 2019, Pharmacological research.

[42]  C-L Wang,et al.  Long non-coding RNA NEAT1 promotes viability and migration of gastric cancer cell lines through up-regulation of microRNA-17. , 2018, European review for medical and pharmacological sciences.

[43]  Hongying Zhu,et al.  Long non‑coding nuclear paraspeckle assembly transcript 1 acts as prognosis biomarker and increases cell growth and invasion in cervical cancer by sequestering microRNA‑101. , 2017, Molecular medicine reports.

[44]  S. Ren,et al.  Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. , 2015, Oncology reports.

[45]  Aimin Li,et al.  PLEK: a tool for predicting long non-coding RNAs and messenger RNAs based on an improved k-mer scheme , 2014, BMC Bioinformatics.

[46]  P. Jagodziński,et al.  Long non-coding RNA as potential biomarkers in non-small-cell lung cancer: What do we know so far? , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[47]  James C. Hu,et al.  The Gene Ontology Resource: 20 years and still GOing strong , 2019 .

[48]  M. Cheng,et al.  The Wnt3a/β-catenin/TCF7L2 signaling axis reduces the sensitivity of HER2-positive epithelial ovarian cancer to trastuzumab. , 2020, Biochemical and biophysical research communications.

[49]  Liang Han,et al.  Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[50]  F. Cappuzzo,et al.  Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer , 2009, Oncogene.

[51]  A. Theocharis,et al.  Proteoglycans remodeling in cancer: Underlying molecular mechanisms. , 2017, Matrix biology : journal of the International Society for Matrix Biology.

[52]  N. Kosaka,et al.  Extracellular vesicles in lung microenvironment and pathogenesis. , 2015, Trends in molecular medicine.

[53]  G. Marshall,et al.  The Novel Long Noncoding RNA linc00467 Promotes Cell Survival but Is Down-Regulated by N-Myc , 2014, PloS one.

[54]  Xin Ma,et al.  LncRNAs Expression Signatures of Renal Clear Cell Carcinoma Revealed by Microarray , 2012, PloS one.

[55]  Xueqin Chen,et al.  Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway , 2017, Oncology letters.

[56]  Shao-Gang Ma,et al.  Suppression of long non‐coding RNA TNRC6C‐AS1 protects against thyroid carcinoma through DNA demethylation of STK4 via the Hippo signalling pathway , 2019, Cell proliferation.

[57]  Kun Xu,et al.  LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC , 2019, Molecular therapy. Nucleic acids.

[58]  Trey Ideker,et al.  Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..

[59]  M. Pan,et al.  Protein Arginine Methyltransferase 3 Enhances Chemoresistance in Pancreatic Cancer by Methylating hnRNPA1 to Increase ABCG2 Expression , 2018, Cancers.

[60]  Ye Zhang,et al.  Ferritin Light Chain (FTL) competes with long noncoding RNA Linc00467 for miR-133b binding site to regulate chemoresistance and metastasis of colorectal cancer. , 2020, Carcinogenesis.

[61]  Yi Zhao,et al.  Utilizing sequence intrinsic composition to classify protein-coding and long non-coding transcripts , 2013, Nucleic acids research.

[62]  Kwok-Kin Wong,et al.  Non-small-cell lung cancers: a heterogeneous set of diseases , 2014, Nature Reviews Cancer.

[63]  M. Lai,et al.  Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and a Systematic-Analysis of Microarray Databases , 2016, PloS one.

[64]  Yufeng He,et al.  Knockdown of LINC00467 contributed to Axitinib sensitivity in hepatocellular carcinoma through miR-509-3p/PDGFRA axis , 2020, Gene Therapy.

[65]  Chi Zhang,et al.  Knockdown of long non-coding RNA NEAT1 inhibits glioma cell migration and invasion via modulation of SOX2 targeted by miR-132 , 2018, Molecular Cancer.

[66]  Yongshuai Jiang,et al.  LncRNA Structural Characteristics in Epigenetic Regulation , 2017, International journal of molecular sciences.

[67]  H. Cao,et al.  Genome-wide profiling of long non-coding RNA expression patterns in the EGFR-TKI resistance of lung adenocarcinoma by microarray. , 2016, Oncology reports.